Epidemiology of the dementias: Recent developments and new approaches

Journal of Neurology Neurosurgery and Psychiatry

Volumn 60, Issue 5, 1996, Pages 478-488

  Van Duijn, C M ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; CLINICAL FEATURE; DEMENTIA; DEPRESSION; DOWN SYNDROME; EDUCATION; ESTROGEN THERAPY; GEOGRAPHIC DISTRIBUTION; HEAD INJURY; HEREDITY; HUMAN; LEWY BODY; MATERNAL AGE; MULTIINFARCT DEMENTIA; OCCUPATIONAL EXPOSURE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; SMOKING; THYROID DISEASE; TIME;

EID: 0029984599     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.60.5.478     Document Type: Review

References (153)

1. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 1991;20:381-90.
2. Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 findings. Ann Neurol 1991;381:381-90.
3. Breteler MMB, Claus JJ, van Duijn CM, et al. Epidemiology of Alzheimer's disease. Epidemiol Rev 1992; 14:59-82.
4. Nilsson LV. Incidence of severe dementia in an urban sam ple followed from 70-79 years of age. Acta Psychiatr Scand 1984;70:478-86.
5. Rorsman B, Hagnell O, Lanke J. Prevalence and incidence of senile and multi-infarct dementia in the Lundby study: a comparison of the time periods 1947-1957 and 1957-1972. Neuropsychobiology 1986; 15:122-9.
6. Aronson MK, Ooi WL, Geva DL. Dementia. Age-dependent incidence, prevalence and mortality in the old old. Arch Intern Med 1991;151:989-92.
7. Li G, Shen YC, Chen CH, et al. A three-year follow-up study of age-related dementia in an urban area of Beijing. Acta Psychiatr Scand 1991;83:99-104.
8. Copeland JRM, Davidson IA, Dewey ME, et al. Alzheimer's disease, other dementia, depression and pseudo-dementia: prevalence, incidence and three-year outcome in Liverpool. Br J Psychiatry 1992;161:230-9.
9. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and Alzheimer's disease in a general population: the Framingham Study. Neurology 1993;43:515-9.
10. Morgan K, Lilley JM, Arie T, et al. Incidence of dementia in a representative British sample. Br J Psychiatry 1993; 163:467-70.
11. Kokmen E, Beard CM, O'Brien PC, et al. Is the incidence of dementing illnes changing? A 25-year time trend study in Rochester, Minnesota (1960-1984). Neurology 1993;43:1887-92.
12. Boothby H, Blizard R, Livingston G, Mann AH. The Gospel Oak Study stage III: the incidence of dementia. Psychobiol Med 1994;24:89-95.
13. Bickle H, Cooper B. Incidence and relative risk of dementia in an urban elderly population. Findings of a prospective field study. Psychobiol Med 1994;24:179-92.
14. Letenneur L, Commenges RD, Dartigues JF, Saberger-Gateau P. Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France. Int J Epidemiol 1994;23:1256-61.
15. Paykel ES, Brayne C, Huppert F, et al. Incidence of dementia in a population older than 75 years in the United Kingdom. Arch Gen Psychiatry 1994;51:325-32.
16. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995;273:1354-9.
17. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population. The Hisayama study. Neurology 1995;45:1161-8.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed revised. Washington, DC: American Psychiatric Association, 1980.
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:39-44.
20. Jorm AF. Cross-national comparison of the occurrence of Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 1991;240:218-22.
21. Skoog I, Nilsson L, Palmertz B, et al. A population-based study of dementia in 85-year-olds. N Engl J Med 1993;328:153-8.
22. Heyman A, Fillenbaum G, Prosnitz B, et al. Estimated prevalence of dementia among elderly black and white community residents. Arch Neurol 1991;48:594-8.
23. Rorsman B, Hagnell O, Lanke J. Prevalence of age psychosis and mortality among aged psychotics in the Lundby study. Neuropsychology 1985;13:167-72.
24. Beard CM, Kokmen E, O'Brien PC, Kurland LT. Are patients with Alzheimer's disease surviving longer in recent years? Neurology 1994;44:1869-71.
25. Cumlings CL. The failing brain. Lancet 1995;345:1481-9.
26. Goate A, Chartier-Harlin M-C, Mullan M, et al. Seggregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6.
27. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-60.
28. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995;269:973-7.
29. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with a missense mutation in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376: 775-8.
30. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:1977-81.
31. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
32. Chartier-Harlin MC, Parfitt M, Legrain S, et al. Apolipoprotein E, ε4 allele as a major risk factor for sporadic early and late-onset form of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Molec Genet 1994;3:569-74.
33. Van Duijn CM, de Knijff P, Cruts M, et al. Apolipoprotein E ε4 allele in a population-based study of early-onset Alzheimer's disease. Nature Genet 1994;7: 74-8.
34. Van Dijk PTM, Dippel DWJ, Habbema JDF. Survival of patients with dementia. J Am Geriatr Soc 1991;39: 603-10.
35. Katzman R, Hill LR, Yu ES, et al. The malignancy of dementia. Predictors of mortality in clinically diagnosed dementia in a population survey of Shanghai, China. Arch Neurol 1994;51:1220-5.
36. Chen JY, Stern Y, Sano M, Mayeux R. Cumalative risk of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease. Arch Neurol 1991;48:1141-3.
37. Risse SC, Lampe TH, Bird TD, et al. Myoclonus, seizures, and paratonia in Alzheimer's disease. Alzheimer Dis Assoc Disord 1990;4:217-25.
38. Knesevich JW, Toro FR, Morris JC, et al. Aphasia, family history, and the longitudinal course of senile dementia of the Alzheimer type. Psychiatry Res 1985;14: 255-63.
39. Molsa PK, Martilla RJ, Rinne UK. Long term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 1995;91: 159-64.
40. Stern Y, Mayeux R, Chen JY, et al. Predictors of mortality in Alzheimer's disease. Ann Neurol 1989;26:132.
41. Kennedy AM, Neuman SK, Frackowiak RS, et al. Chromosome 14 linked familial Alzheimer's disease. A clinico-pathological study of a single pedigree. Brain 1995;118:185-205.
42. Haltia M, Viitanen M, Sulkava R, et al. Chromosome 14-encoded Alzheimer's disease: genetic and clinicopathological description. Ann Neurol 1994;36:362-7.
43. Lampe TH, Bird TD, Nochlin D, et al. Phenotype of chromosome 14-linked familial Alzheimer's disease in a large kindred. Ann Neurol 1994;36:368-78.
44. Farrer LA, Cupples LA, Van Duijn CM, et al. Rate of progression of Alzheimer's disease is associated with genetic risk. Arch Neurol 1995;52:918-23.
45. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 1995;45:1323-8.
46. Basun H, Grut M, Winblad B, Lannfelt L. Apolipoprotein epsilon 4 allele and disease progression in patients with late-onset Alzheimer's disease. Neurosci Lett 1995;183: 32-4.
47. Frisoni GB, Govoni S, Geroldi C, et al. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995;37:596-604.
48. Van Duijn CM, de Knijff P, Wehnert A, et al. The apolipoprotein E ε2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 1995;37:605-10.
49. Pantoni L, Garcia JH. The significance of white matter abnormalities 100 years after Binswanger's report. Stroke 1995;26:1293-301.
50. Tournier-Lasserve E, Joutel A, Melki J, et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nature Genet 1993;3:256-9.
51. Chabriat H, Vahedi K, Iba-Zizen MT, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995;346:934-9.
52. Hier DB, Wallace JD, Gorelick PB, et al. Predictors of survival in clinically diagnosed Alzheimer's disease and multi-infarct dementia. Arch Neurol 1989;46: 1213-6.
53. Van Duijn CM, Stijnen T, Hofman A. Risk factors for Alzheimer's disease: overview of the collaborative reanalysis of case-control studies. Int J Epidemiol 1991;20 (suppl):S4-12.
54. Van Duijn CM, Clayton D, Chandra V, et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20 (suppl):S13-20.
55. Rocca WA, van Duijn CM, Chandra V, et al. Maternal age and Alzheimer's disease: a collaborative re-analysis of case-control studies. Im J Epidemiol 1991;20 (suppl): S21-7.
56. Mortimer JA, van Duijn CM, Chandra V, et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20 (suppl):S28-35.
57. Breteler MMB, van Duijn CM, Chandra V, et al. Medical history and the risk of Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20(suppl):S36-42.
58. Jorm AF, van Duijn CM, Chandra V, et al. Psychiatric history and related exposures as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20(suppl):S43-7.
59. Graves AB, van Duijn CM, Chandra V, et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20(suppl):S48-S57.
60. Graves AB, van Duijn CM, Chandra V, et al. Occupational exposures to solvent and lead as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20 (suppl): S58-61.
61. Shimano H, Murase T, Ishibashi S, et al. Plasma apolipoproteins in patients with multi-infarct dementia. Atherosclerosis 1989;79:257-60.
62. Frisoni GB, Geroldi C, Bianchetti A, et al. Apolipoprotein E epsilon 4 allele frequency in vascular dementia and Alzheimer's disease. Stroke 1994;25:1703-4.
63. St Clair D, Norrman J, Perry R, et al. Apolipoprotein E epsilon 4 allele frequency in patients with Lewy body dementia, Alzheimer's disease and age-matched controls. Neurosci Lett 1994;176:45-6.
64. Amouyel P, Vidal O, Launay JM, Laplanche JL. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet 1994;344:1315-8.
65. Reed T, Carmelli D, Swan GE, et al. Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. Arch Neurol 1994;51: 1189-92.
66. Feskes E, Havekes LM, Kalmijn S, et al. Apolipoprotein E4 allele and congnitive decline in elderly men. BMJ 1994;309:1202-6.
67. Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E allele E4, dementia and cognitive decline in a population sample. Lancet 1995;346:1387-90.
68. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273:1274-8.
69. Van Gool WA, Evenhuis HM, van Duijn CM, on behalf of the Dutch Study Group on Down's Syndrome and Ageing. A case-control study of apolipoprotein E genotypes in Alzheimer's disease with Down's syndrome. Ann Neurol 1995;38;225-30.
70. Payami H, Montee KR, Kaye JA, et al. Alzheimer's disease, apolipoprotein E4, and gender (letter). JAMA 1994;271:1316-7.
71. Corder EH, Saunders AM, Strittmatter WJ, et al. The apolipoprotein E ε4 allele and sex-specific risk of Alzheimer's disease. JAMA 1995;273:373-74.
72. Jarvik GP, Wijsman EM, Kukull WA, et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-6.
73. Hendrie HC, Hall KS, Hui S, et al. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol 1995;37: 118-20.
74. Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer's disease: ethnic variation in genotypic risks. Ann Neurol 1995;37:254-59.
75. Hendrie HC, Hall KS, Hui S, et al. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol 1995;37: 118-20.
76. Rebeck GW, Peris TT, West HL, et al. Reduced apolipoprptein epsilon 4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals Neurology 1994;44:1513-6.
77. Lannfelt L, Lilius L, Nastase M, et al. Lack of association between apolipoprotein E allele epsilon 4 and sporadic Alzheimer's disease. Neurosci Lett 1994;169:175-8.
78. Sobel E, Louhija J, Sulkava R, et al. Lack of association of apolipoprotein E allele epsilon 4 with late-onset Alzheimer's disease among Finnish centenarians. Neurology 1995;45:903-7.
79. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet 1994;7:180-4.
80. Sorbi S, Nacmias B, Forleo P, et al. ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease Neurosci Lett 1994;177:100-2.
81. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995;92: 4725-7.
82. Holland AJ, Oliver C. Down's syndrome and the links with Alzheimer's disease. J Neurol Neurosurg, Psychiatry 1995;59:111-4.
83. Mendez MF, Underwood KL, Zander BA, et al. Risk factors in Alzheimer's disease: a clinicopathologic study. Neurology 1992;42:770-5.
84. Li G, Shen YC, Li YT, et al. A case-control study of Alzheimer's disease in China. Neurology 1992;42: 1481-8.
85. Fratiglioni L, Ahlbom A, Viitanen M, Winblad B. Risk factors for late-onset Alzheimer's disease: a population-based, case-control study. Ann Neurol 1993;33:258-66.
86. Prince M, Cullen M, Mann A. Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial. Neurology, 1994 44:97-104.
87. Sadovnick AD, Yee IM, Hirst C. The rate of the Down syndrome among offspring of women with Alzheimer disease. Psychiatric Genetics 1994;4:87-9.
88. Forster DP, Newens AJ, Kay DW, Edwardson JA. Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England. J Epidemiol Comm Health 1995;49:253-8.
89. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 1994;44: 2073-80.
90. Yatham LN, McHale PA, Kinsella A. Down syndrome and its association with early-onset Alzheimer's disease. Acta Psychiatry Scand 1988;77:38-41.
91. Berr C, Borghi E, Rethore MO, et al. Absence of familial association between dementia of the Alzheimer type and Down syndrome. Am J Med Genet 1989;33:545-50.
92. Schupf N, Kapell D, Lee JH, et al. Increased risk of Alzheimer's disease in mothers of adults with Down's syndrome. Lancet 1994;344:353-6.
93. Van Duijn CM, Clayton DG, Chandra V, et al. Interaction between genetic and environmental risk factors for Alzheimer's disease: a reanalysis of case-control studies. Genet Epidemiol 1994;11:539-51.
94. De Vos RA, Jansen EN, Stam FC et al. 'Lewy body disease': clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 1995;97:13-22.
95. Saitoh T, Xia Y, Chen X, et al. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol 1995;37:110-2.
96. Chen X, Xia Y, Alford M, et al. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Ann Neurol 1995;38:653-8.
97. Farrer LA, Cupples LA, Connor L, et al. Association of decreased paternal age and late-onset Alzheimer's disease. Arch Neurol 1991;48:599-604.
98. Mayeux R, Ottman R, Tang MX, et al. Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community-dwelling elderly persons and their first-degree relatives. Ann Neurol 1993;33: 494-501.
99. Rasmussen DX, Brandt J, Martin DB, Folstein MF. Head injury as a risk factor in Alzheimer's disease. Brain Injury 1995;9:213-9.
100. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease. Neurology 1995;45:555-7.
101. Roberts GW, Gentleman SM, Lynch A, et al. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1994;57: 419-25.
102. Luchins DJ, Cohen D, Hanrahan P, et al. Are there clinical differences between familial and non-familial Alzheimer's disease? Am J Psychiatry 1992;149:1023-7.
103. Percy ME, Dalton AJ, Markovic VD, et al. Autoimmune thyroiditis associated with mild "subclinical" hypothyroidism in adults with Down syndrome: a comparison of patients with and without manifestations of Alzheimer's disease. Am J Med Genet 1990;36:140-54.
104. Ewins DL, Rossor MN, Butler J, et al. Association between autoimmune thyroid disease and familial Alzheimer's disease. Clin Endocrinol 1991;35:93-6.
105. Kokmen E, Beard CM, Chandra V, et al. The association between Alzheimer's disease and thyroid disease in Rochester, Minnesota. Neurology 1991;41:1745-7.
106. Skoog I. Risk factors for vascular dementia: a review. Dementia 1994;5:137-44.
107. Verny M, Duyckaerts C, Pierot L, Hauw JJ. Leuko-araiosis. Dev Neurosci 1991;13:245-50.
108. Scheltens P, Barkhof F, Valk J, et al. White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain 1992;115:735-18.
109. Bots ML, van Swieten JC, Breteler MMB, et al. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet 1993;341:1232-7.
110. Dash PK, Moore AN. Enhanced processing of APP induced by IL-I beta can be reduced by indomethacin and nordihydroguaiaretic acid. Biochem Biophys Res Commun 1995;208:542-8.
111. Brugg B, Dubreuil YL, Huber G, et al. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci USA 1995; 92:3032-5.
112. Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994;44:227-32.
113. Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-6.
114. Andersen K, Launer LJ, Ort A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995;45:1441-5.
115. Beard CM, Kokmen E, Kurland T. Rheumatoid arthritis and susceptibility to Alzheimer's disease. Lancet 1991; 337:1426,
116. Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-5.
117. Honjo H, Tanaka K, Kashiwagi T, et al. Senile dementia-Alzheimer's type and estrogen. Horm Metab Res 1995; 27:204-7.
118. Brenner DE, Kukull WA, Stergachis A, et al. Post-menopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994;140:262-7.
119. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256-61.
120. Henderson VW, Paganini-Hill A, Emanuel CK, et al. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51: 896-900.
121. Hebert LE, Scherr PA, Becken LA, et al. Relation of smoking and alcohol consumption to incident Alzheimer's disease. Am J Epidemiol 1992;135:347-55.
122. Brenner DE, Kukull WA, van Belle G, et al. Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study. Neurology 1993; 43:293-300.
123. Letenneur L, Dartigues JF, Commenges D, et al. Tobacco consumption and cognitive impairment in elderly people. A population-based study. Ann Epidemiol 1994;4: 449-54.
124. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994;13: 131-14.
125. Van Duijn CM, Havekes LM, Van Broeckhoven C, et al. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ 1995;310:627-31.
126. Plassman BL, Helms MJ, Welsh KA, et al. Smoking, Alzheimer's disease, and confounding with genes (letter). Lancet 1995;345:387.
127. Nitta A, Katono Y, Itoh A, et al. Nicotine reverses scopolamine-induced impairment of performance in passive avoidance task in rats through its action on the dopaminergic neuronal system. Pharmacol Biochem Behav 1995;49:807-12.
128. Newhouse PA, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuropsychopharmacology 1994;10:93-107.
129. Jones GM, Sahakian BJ, Levy R, et al. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 1992;108:485-94.
130. Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav 1995;51:509-14.
131. Morens DM, Grandinetti A, Reed D, et al. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995;45: 1041-51.
132. Saunders PA, Copeland JR, Dewey ME, et al. Heavy drinking as as risk factor for depression and dementia in elderly men. Finding from the Liverpool longitudinal study. BrJ Psychiatry 1991;159:213-6.
133. Kukull WA, Larson EB, Bowen JD, et al. Solvent exposure as a risk factor for Alzheimer's disease: a case-control study. Am J Epidemiol 1995;141:1059-71.
134. Edling C, Ekberg K, Ahlborg G Jr, et al. Long-term follow-up of workers exposed to solvents. Br J Ind Med 1990;47:75-82.
135. Landsberg JP, McDonald B, Watt F. Absence of aluminium in neuritic plaque cores in Alzheimer's disease. Nature 1992;360:65-8.
136. Kawahara M, Muramoto K, Kobayashi K, et al. Aluminum promotes the aggregation of Alzheimer's amyloid beta-protein in vitro. Biochem Biophys Res Commun 1994;198:531-5.
137. Fasman GD, Perczel A, Moore CD. Solubilization of beta-amyloid-(1-42)-peptide: reversing the beta-sheet conformation induced by aluminum with silicates. Proc Natl Acad Sci USA 1995;92:369-71.
138. Scott CW, Fieles A, Sygowski LA, Caputo CB. Aggregation of tau protein by aluminum. Brain Res 1993;628: 77-84.
139. Candy JM, McArthur FK, Oakley AE, et al. Aluminium accumulation in relation to senile plaque and neurofibrillary tangle formation in the brains of patients with renal failure. J Neurol Sci 1992;107:210-8.
140. Harrington CR, Wischik CM, McArthur FK, et al. Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet 1994;343:993-7.
141. Doll R. Review: Alzheimer's disease and environmental survival bias. Age Ageing 1993;22:138-53.
142. Jacqmin H, Commenges D, Letenneur L, et al. Components of drinking water and risk of cognitive impairment in the elderly. Am J Epidemiol 1994;139:48-57.
143. Rifat SL, Eastwood MR, McLachlan DR, et al. Effect of exposure of miners to aluminium powder. Lancet 1990; 336:1162-5.
144. Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991;337:1304-8.
145. Edwardson JA, Moore PB, Ferrier IN, et al. Effect of silicon on gastrointestinal absorption of aluminium. Lancet 1993;342:211-2.
146. O'Mahony D, Denton J, Templar J, et al. Bone aluminium content in Alzheimer's disease. Dementia 1995; 6:69-72.
147. Zapatero MD, Garcia de Jalon A, Pascual F, et al. Serum aluminium levels in Alzheimer's disease and senile dementias. Biol Trace Elem Res 1995;47:235-40.
148. Fosmire GJ, Focht SJ, McClearn GE. Genetic influences on tissue deposition of aluminum in mice. Biol Trace Elem Res 1993;37:115-21.
149. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology 1993;43:13-20.
150. Beard CM, Kokmen E, Offord KP, Kurland LT. Lack of association between Alzheimer's disease and education, occupation, marital status, or living arrangement. Neurology 1992;42:2063-8.
151. Cobb JL, Wolf PA, Au R, et al. The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology 1995;45: 1707-12.
152. Stern Y, Tang MX, Denaro J, Mayeux R. Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. Ann Neurol 1995;37:590-5.
153. Moritz DJ, Petitti DB. Association of education with reported age of onset and severity of Alzheimer's disease at presentation: implications for the use of clinical samples. Am J Epidemiol 1993;137:456-62.